Modality
Radioligand
MOA
CD47i
Target
IL-23
Pathway
RAS/MAPK
OCDPNHParkinson's
Development Pipeline
Preclinical
Oct 2017
→ Oct 2030
PreclinicalCurrent
NCT07471375
1,388 pts·OCD
2021-10→2030-10·Recruiting
NCT05594949
2,062 pts·Parkinson's
2017-10→2027-11·Not yet recruiting
3,450 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-11-201.6y awayInterim· Parkinson's
2030-10-014.5y awayInterim· OCD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Not yet…
Preclinical
Recruit…
Catalysts
Interim
2027-11-20 · 1.6y away
Parkinson's
Interim
2030-10-01 · 4.5y away
OCD
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07471375 | Preclinical | OCD | Recruiting | 1388 | CR |
| NCT05594949 | Preclinical | Parkinson's | Not yet recr... | 2062 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |